Document:

Schedules to Security Agreement

 EXHIBIT 10.10 
 Schedule 3.1(a) 
 Subsidiaries of Accentia Biopharmaceuticals, Inc. 
 Subsidiaries shall mean (1): 
 Analytica International, Inc., a
Florida corporation (2) 
 Teamm Pharmaceuticals, Inc., a Florida corporation d/b/a Accentia Pharmaceuticals (3) 
 Accentia Specialty Pharmacy, Inc., a Florida corporation 
 Accent RX, Inc., a
Florida corporation (inactive) 
 Indirect Subsidiaries shall mean: 
 Analytica International GmbH f/k/a Imor International GmbH a corporation organized in Germany is 100% owned by Analytica International, Inc. 
 (1) The Accentia Biopharmaceuticals, Inc. owns approximately 76% of Biovest International, Inc., a Delaware corporation subject to outstanding warrants and debenture exchange rights granted by the Company.
Biovest International, Inc. (BVTI.OB) is a publicly traded and reporting company and by agreement is excluded from the definition of Subsidiary for all purposes of this agreement and the related transaction documents. 
 (2) Each of the Company’s subsidiaries and their assets are subject to a lien imposed by existing notes held by Laurus Master Fund, Ltd. However, upon the
closing of the Debentures, the Company and Laurus will enter into a Payoff Transaction, pursuant to which all of the collateral pledged to Laurus will be released with the exception that Laurus will continue to have a first security interest in all
of the capital stock and assets of Analytica International, Inc. and the Company’s interest in the BiovaxID royalty and the BiovaxID royalty agreement between the company and Biovest International, Inc. Laurus will have a preemptive right to
acquire all of the capital stock of Analytica International Inc. 
 (3) Each of the Company’s subsidiaries and their assets are subject to a lien
imposed by an existing note held by Southwest Bank f/k/a Missouri State Bank. However, upon the closing of the Debentures, the Company and Southwest will enter into an Amendment to the Revolving Note Transaction, pursuant to which all of the
collateral pledged to Southwest will be released with the exception that Southwest will have a first security interest in the inventory and accounts receivable of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals together with
15 million common stock shares of Biovest International, Inc. currently owned by the Company. 
 (4) Each of the Company’s subsidiaries and
their assets are subject to a lien imposed by an agreement between McKesson Corporation and the Company. However, upon the closing of the Debentures, the Company and McKesson will enter into an Amendment to the Termination Agreement Transaction,
pursuant to which to which all of the collateral pledged to McKesson will be released with the exception that McKesson will retain a first security interest in the common stock shares of Biovest International, Inc. currently owned by the Company.

 Accentia Biopharmaceuticals, Inc. 
 Schedule 3.1(g) 
 Capitalization Chart 
 June 16, 2008 
  

			
	 Total common shares outstanding
	  	47,683,888
	 Shares issuable upon conversion of Midsummer I Conv Debenture - $1.25/share
(also exchangeable into Biovest shares owned by
Accentia)
	  	7,005,559
	 Shares issuable upon conversion of Midsummer II Conv Debenture - $1.25/share
	  	15,476,118
	 Shares issueable upon conversion of Preferred Transaction - $1.25/share
	  	6,983,200
	 Outstanding warrants
	  	20,824,000
	 Outstanding options
	  	4,315,358
		  	 
	 Fully diluted common shares
	  	102,288,123
		  	 

					
	Schedule 3.1(g) Continued One	 	 Total Shares
	  	
		 	 Outstanding
	  	
		 	         47,683,888
	  	
		
	Below is a list of Affiliates which includes Directors, Officers, and 5% shareholders.	  	
	
	Shares listed include stock owned as well as all outstanding options and warrants (vested and non-vested).

  

														
	 	  	 	  	 	 	 	Calculation of Beneficially Owned Shares
	 5% Stockholders
	  	Number of Shares of
Common Stock
Beneficially
Owned	  	% of
Total Outstanding
Shares	 	 	Issued
Stock	  	All
Outstanding
Options	  	All
Outstanding
Warrants	  	Total
	 The Hopkins Capital Group, LLC (1)
	  	4,385,992	  	9.20	%	 	4,385,992	  	—  	  	—  	  	4,385,992
	 Timothy D. Ryll (2)
	  	4,163,926	  	8.73	%	 	4,163,926	  	—  	  	—  	  	4,163,926
	 Pharmaceutical Product Development, Inc. (3)
	  	4,270,323	  	8.96	%	 	4,270,323	  	—  	  	—  	  	4,270,323
							
	 Named Executive Officers and Directors
	  	 	  	 	 	 	 	  	 	  	 	  	 
	 Francis E. O Donnell, Jr., M.D. (4)
	  	7,851,136	  	16.46	%	 	5,673,884	  	2,252	  	2,175,000	  	7,851,136
	 Steven R. Arikian, M.D.
	  	1,175,556	  	2.47	%	 	950,544	  	225,012	  	—  	  	1,175,556
	 Samuel S. Duffey, Esq.
	  	826,101	  	1.73	%	 	—  	  	826,101	  	—  	  	826,101
	 Alan M. Pearce (5)
	  	1,389,802	  	2.91	%	 	712,521	  	677,281	  	—  	  	1,389,802
	 David M. Schubert
	  	127,500	  	0.27	%	 	—  	  	127,500	  	—  	  	127,500
	 Edmund King
	  	95,000	  	0.20	%	 	—  	  	95,000	  	—  	  	95,000
	 William S. Poole
	  	65,000	  	0.14	%	 	—  	  	65,000	  	—  	  	65,000
	 Christopher C. Chapman
	  	52,500	  	0.11	%	 	—  	  	52,500	  	—  	  	52,500

  

	-1	Voting and investment power over the shares held by The Hopkins Capital Group, LLC (“Hopkins”) is exercised by its manager, Dr. Francis E. O’Donnell, Jr.,
our Chairman and Chief Executive Officer. 

  

	-2	Includes: 

  

	 	(a)	3,617,660 shares of common stock held by MOAB Investments, LP (“MOAB”) and 428,573 shares of our common stock held by MOAB-II Investments, LP (“MOAB-II” and,
together with MOAB, the “MOAB Entities”) and 

  

	 	(b)	117,693 shares of common stock held by Timothy D. Ryll, as the Trustee of three different trusts (the “Timothy Ryll Trusts”). 

 Mr. Timothy Ryll is the sole shareholder and sole director of MOAB Management Company, Inc., which is the sole general partner of each of the MOAB
Entities. Mr. Timothy Ryll is the trustee of the Timothy Ryll Trusts. Mr. Timothy Ryll is the son of Dr. Dennis Ryll, one of our former directors. Dr. Dennis Ryll, a limited partner in each of the MOAB Entities, exercises no
voting or investment power over any of our shares held by the MOAB Entities or the Timothy Ryll Trusts. Mr. Timothy Ryll exercises voting and investment power over the MOAB Entities and over the Timothy Ryll Trusts. 
  

	-3	These shares are held by Pharmaceutical Product Development International Holdings, Inc., or PPD International, a selling shareholder and a wholly owned subsidiary of Pharmaceutical
Product Development, Inc. (“PPD”), a publicly held corporation. PPD exercises voting and investment control over PPD International. 

  

	-4	Includes: 

  

	 	(a)	4,385,992 shares of common stock held by Hopkins, 412,892 shares of common stock and 2,175,000 warrants held by The Hopkins Capital Group II, LLC (“Hopkins II”) and
875,000 shares of common stock held by Hopkins Capital Partners, Inc. 

  

	 	(b)	Dr. O’Donnell holds voting and investment power over shares held by each of Hopkins and Hopkins II as its manager and Hopkins Capital Partners, Inc. as its owner

  

	-5	Includes: 

  

	 	(a)	95,003 shares of common stock held by The Pearce Family Limited Partnership; 

  

	 	(b)	380,011 shares of common stock held jointly by Mr. Pearce and his wife. 

  

	 	(c)	As a general partner of The Pearce Family Limited Partnership, Mr. Pearce exercises voting and investment power over The Pearce Family Limited Partnership.

 Schedule 3.1(g) continued two - The Company is subject to the following First Rights of Refusal in connection with the
Securities previously granted to the following parties. The Company has either complied with or obtained waivers of the existing participation rights listed herein. 
 The 8% Debentures financing dated September 29, 2006 
 Midsummer Investment Ltd. 
 Whitebox Convertible Arbitrage, Ltd. 
 Whitebox Hedged High Yield Partners

 Guggenheim Portfolio 
 GPC LIX 
 Pandora Select Partners 
 Whitebox Intermarket Partners 
 Wolverine Convertible 
 Rockmore Investment 
 Laurus Master Fund 
 The 8% Debentures financing dated
February 27, 2007 
 Midsummer Investment Ltd. 
 Whitebox Convertible Arbitrage, Ltd. 
 Whitebox Hedged High Yield Partners 
 Guggenheim Portfolio 
 GPC LIX 
 Pandora Select Partners 
 Whitebox Intermarket Partners 
 Whitebx Special Opportunities Partners 
 Wolverine Convertible 
 Rockmore Investment 
 UBS O’Connor LLC 
 BridgePointe Master Fund 
 GCA Strategic Fund 
 Diamond
Opportunity Fund 
 Lloyd Miller 
 Crescent International

 Cranshire Capital 
 R&R Opportunity Fund 
 The Convertible Preferred Stock financing dated January 18, 2008 
 Valens U.S. SPV I, LLC 
 Valens Offshore SPV I, Ltd. 
 BAM Opportunity Fund LP 
 Hudson Bay Fund, LP 
 Hudson
Bay Overseas Fund, Ltd 
 RRC Bio Fund, LP 
 Cranshire Capital,
L.P. 
 Rosalind Capital Partners L.P. 
 Biohedge Holdings Limited

 Diamond Opportunity Fund, LLC 
 Rockmore Investment Master
Fund, Ltd. 
 BridgePointe Master Fund, Ltd. 

 GCA Strategic Investment Fund Limited 
 The following authorizations are required for the issuance of the Securities: 
 Board of Directors’ authorization

									
	Accentia Biopharmaceuticals, Inc.	  	OUTSTANDING AND EXERCISABLE BY PRICE	  		  	Page:	  	1            
	 	  	AS OF 6/6/2008	  	 	  	File:	  	Osprice
	 	  	Plan is equal to warr	  	 	  	Date:	  	6/12/2008
	 	  	 	  	 	  	Time:	  	3:42:43 PM

  

																		
	 Name
	  	 ID
	  	 Number
	  	 Warrant
Date
	  	 Expiration
Date
	  	 Remaining
Life in Years
	  	Warrant
Price	  	 Shares
Outstanding
	  	 Shares
Exercisable

	 Ascendiant Securities LLC, Ascendiant Securities
	  		  	00001513	  	2/27/2007	  	2/28/2012	  	3.73	  	$	3.660	  	75,000	  	75,000
	 Ascendiant Securities LLC, Ascendiant Securities
	  		  	00001514	  	2/27/2007	  	2/28/2012	  	3.73	  	$	3.660	  	50,000	  	50,000
	 BAM Opportunity Fund LP,
	  		  	00001670	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	561,797	  	561,797
	 BioHedge Holdings Limited,
	  		  	00001664	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	5,805	  	5,805
	 Black Knight Venture Fund I, Black Knight Venture Fund I
	  		  	00001461	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	200,000	  	200,000
	 Bridgepointe Master Fund LTD, Bridgepointe Master Fund LTD
	  		  	00001485	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	189,732	  	189,732
	 Bridgepointe Master Fund LTD, Bridgepointe Master Fund LTD
	  		  	00001661	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	93,632	  	93,632
	 Brio Capital LP, Brio Capital LP
	  		  	00001460	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	10,000	  	10,000
	 Bristol Investment Fund, Ltd., Bristol Investment Fund, Ltd.
	  		  	00001459	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	30,000	  	30,000
	 Carol A. Sassouni Rev. Trust, Carol A. Sassouni Rev. Trust
	  		  	00001449	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	1,000	  	1,000
	 Cranshire Capital, LP, Cranshire Capital, LP
	  		  	00001458	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	50,000	  	50,000
	 Cranshire Capital, LP, Cranshire Capital, LP
	  		  	00001490	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	94,866	  	94,866
	 Cranshire Capital, LP, Cranshire Capital, LP
	  		  	00001534	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	70,225	  	70,225
	 Cranshire Capital, LP, Cranshire Capital, LP
	  		  	00001666	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	93,632	  	93,632
	 Crescent International, Ltd, Crescent International, Ltd
	  		  	00001457	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	30,000	  	30,000
	 Crescent International, Ltd, Crescent International, Ltd
	  		  	00001489	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	88,542	  	88,542
	 DKR Sound Shore Oasis Holding, DKR Sound Shore Oasis Holding
	  		  	00001455	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	50,000	  	50,000
	 Diamond Opportunity Fund, LLC, Diamond Opportunity Fund, LLC
	  		  	00001456	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	30,000	  	30,000
	 Diamond Opportunity Fund, LLC, Diamond Opportunity Fund, LLC
	  		  	00001663	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	37,453	  	37,453
	 Diamond Opportunity Fund, LLC, Diamond Opportunity Fund, LLC
	  		  	00001533	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	28,090	  	28,090
	 Diamond Opportunity Fund, LLC, Diamond Opportunity Fund, LLC
	  		  	00001487	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	37,946	  	37,946
	 GCA Strategic Investment Fund, GCA Strategic Investment Fund
	  		  	00001486	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	189,732	  	189,732
	 GCA Strategic Investment Fund, GCA Strategic Investment Fund
	  		  	00001660	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	93,632	  	93,632
	 GPC LIX, LLC, GPC LIX, LLC
	  		  	00001463	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	62,724	  	62,724
	 GPC LIX, LLC, GPC LIX, LLC
	  		  	00001526	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	52,528	  	52,528
	 GPC LIX, LLC, GPC LIX, LLC
	  		  	00001478	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	70,959	  	70,959
	 Guggenheim Portfolio , Guggenheim Portfolio
	  		  	00001477	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	42,374	  	42,374
	 Guggenheim Portfolio , Guggenheim Portfolio
	  		  	00001464	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	37,634	  	37,634
	 Guggenheim Portfolio , Guggenheim Portfolio
	  		  	00001525	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	31,367	  	31,367
	 Holman, Carl Reyburn
	  		  	00001445	  	11/2/2005	  	11/2/2012	  	4.41	  	$	8.000	  	35,000	  	35,000
	 Hopkins Capital Group II, LLC, HCG II, LLC
	  		  	00001517	  	6/14/2007	  	6/14/2011	  	3.02	  	$	4.320	  	2,000,000	  	2,000,000
	 Hopkins Capital Group II, LLC, HCG II, LLC
	  		  	00001543	  	12/27/2007	  	12/27/2012	  	4.56	  	$	2.910	  	175,000	  	175,000
	 Hudson Bay Fund, LP,
	  		  	00001669	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	7,116	  	7,116
	 Hudson Bay Overseas Fund, Ltd,
	  		  	00001668	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	11,610	  	11,610
	 Kamunting Street Master Fund, Kamunting Street Master Fund
	  		  	00001454	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	100,000	  	100,000
	 Laurus Master Fund, Ltd., Laurus Master Fund, Ltd.
	  		  	00001443	  	8/16/2005	  	8/16/2010	  	2.19	  	$	2.670	  	1,000,000	  	1,000,000
	 Laurus Master Fund, Ltd., Laurus Master Fund, Ltd.
	  		  	00001538	  	10/31/2007	  	10/31/2014	  	6.40	  	$	2.670	  	4,024,398	  	4,024,398
	 Laurus Master Fund, Ltd., Laurus Master Fund, Ltd.
	  		  	00001465	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	627,240	  	627,240
	 MOAB Investments, LP
	  		  	00001518	  	6/14/2007	  	6/14/2011	  	3.02	  	$	4.320	  	200,000	  	200,000
	 May, David D
	  		  	00001453	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	5,000	  	5,000
	 Mayo Foundation for Medical Ed, Mayo Foundation for Medical Ed
	  		  	00001441	  	7/20/2006	  	7/20/2011	  	3.12	  	$	3.500	  	25,000	  	25,000
	 Mayo Foundation for Medical Ed, Mayo Foundation for Medical Ed
	  		  	00001442	  	8/22/2006	  	8/22/2011	  	3.21	  	$	3.500	  	450,000	  	300,000
	 Mayo Foundation for Medical Ed, Mayo Foundation for Medical Ed
	  		  	00001442	  	6/16/2008	  	8/22/2011	  	5.00	  	$	1.500	  	1,000,000	  	1,000,000
	 Midsummer Investment, Ltd., Midsummer Investment, Ltd.
	  		  	00001466	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	1,003,584	  	1,003,584
	 Midsummer Investment, Ltd., Midsummer Investment, Ltd.
	  		  	00001522	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	607,304	  	607,304

																		
	 Midsummer Investment, Ltd., Midsummer Investment, Ltd.
	  		  	00001474	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	820,402	  	820,402
	 Miller, Lloyd I
	  		  	00001488	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	126,488	  	126,488
	 Nisswa Master Fund, Ltd., Nisswa Master Fund, Ltd.
	  		  	00001452	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	25,000	  	25,000
	 Nite Capital LP, Nite Capital LP
	  		  	00001451	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	40,000	  	40,000
	 Pandora Select Partners, LP, Pandora Select Partners, LP
	  		  	00001467	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	87,814	  	87,814
	 Pandora Select Partners, LP, Pandora Select Partners, LP
	  		  	00001527	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	73,502	  	73,502
	 Pandora Select Partners, LP, Pandora Select Partners, LP
	  		  	00001479	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	99,294	  	99,294
	 R&R Opportunity Fund, L.P., R&R Opportunity Fund, L.P.
	  		  	00001492	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	31,622	  	31,622
	 R&R Opportunity Fund, L.P., R&R Opportunity Fund, L.P.
	  		  	00001536	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	23,408	  	23,408
	 RAM Holdings, LLC., RAM Holdings, LLC.
	  		  	00001450	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	50,000	  	50,000
	 RRC Bio Fund, LP,
	  		  	00001667	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	59,925	  	59,925
	 Rockmore Investment MasterFund, Rockmore Investment MasterFund
	  		  	00001468	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	125,448	  	125,448
	 Rockmore Investment MasterFund, Rockmore Investment MasterFund
	  		  	00001491	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	52,366	  	52,366
	 Rockmore Investment MasterFund, Rockmore Investment MasterFund
	  		  	00001535	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	38,764	  	38,764
	 Rockmore Investment MasterFund, Rockmore Investment MasterFund
	  		  	00001662	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	93,632	  	93,632
	 Rodman & Renshaw, LLC, Rodman & Renshaw
	  		  	00001473	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	545,455	  	545,455
	 Rodman & Renshaw, LLC, Rodman & Renshaw
	  		  	00001515	  	2/27/2007	  	2/28/2012	  	3.73	  	$	3.660	  	330,918	  	330,918
	 Rodman & Renshaw, LLC, Rodman & Renshaw
	  		  	00001516	  	2/27/2007	  	2/28/2012	  	3.73	  	$	3.660	  	5,682	  	5,682
	 Rodman & Renshaw, LLC, Rodman & Renshaw
	  		  	00001659	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	163,464	  	163,464
	 Rosalind Capital Partners, L.P,
	  		  	00001665	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	14,606	  	14,606
	 Sibex Capital Fund, Inc., Sibex Capital Fund, Inc.
	  		  	00001448	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	30,000	  	30,000
	 Soutine Resources, LLC, Soutine Resources, LLC
	  		  	00001447	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	22,500	  	22,500
	 Telesis CDE Corporation, Telesis CDC Corporation
	  		  	00001444	  	4/25/2006	  	4/24/2013	  	4.88	  	$	8.000	  	100,000	  	100,000
	 UBS O’Connor LLC, UBS O’Connor LLC
	  		  	00001446	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	100,000	  	100,000
	 UBS O’Connor LLC, UBS O’Connor LLC
	  		  	00001484	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	126,488	  	126,488
	 UBS O’Connor LLC, UBS O’Connor LLC
	  		  	00001532	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	93,633	  	93,633
	 Valens Offshore SPV I, Ltd,
	  		  	00001671	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	365,169	  	365,169
	 Valens U.S. SPV I, LLC,
	  		  	00001672	  	1/18/2008	  	1/18/2014	  	5.62	  	$	2.670	  	196,629	  	196,629
	 Whalehaven Capital/Stonestreet, Whalehaven Capital/Stonestreet
	  		  	00001462	  	5/15/2006	  	5/15/2011	  	2.94	  	$	6.590	  	50,000	  	50,000
	 Whitebox Convertible Arbitrage, Whitebox Convertible Arbitrage
	  		  	00001469	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	376,344	  	376,344
	 Whitebox Convertible Arbitrage, Whitebox Convertible Arbitrage
	  		  	00001475	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	299,018	  	299,018
	 Whitebox Convertible Arbitrage, Whitebox Convertible Arbitrage
	  		  	00001523	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	221,349	  	221,349
	 Whitebox Hedged High Yield Prt, Whitebox Hedged High Yield Prt
	  		  	00001470	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	376,344	  	376,344
	 Whitebox Hedged High Yield Prt, Whitebox Hedged High Yield Prt
	  		  	00001476	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	425,506	  	425,506
	 Whitebox Hedged High Yield Prt, Whitebox Hedged High Yield Prt
	  		  	00001524	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	314,982	  	314,982
	 Whitebox Intermarket Partners, Whitebox Intermarket Partners
	  		  	00001471	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	62,724	  	62,724
	 Whitebox Intermarket Partners, Whitebox Intermarket Partners
	  		  	00001528	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	52,528	  	52,528
	 Whitebox Intermarket Partners, Whitebox Intermarket Partners
	  		  	00001480	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	70,959	  	70,959
	 Whitebox Special Opp Fund, LP, Whitebox Special Opp Fund, LP
	  		  	00001482	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	50,595	  	50,595
	 Whitebox Special Opp Fund, LP, Whitebox Special Opp Fund, LP
	  		  	00001529	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	56,180	  	56,180
	 Whitebox Special Opp Fund, LTD, Whitebox Special Opp Fund, LTD
	  		  	00001481	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	75,893	  	75,893
	 Whitebox Special Opp Fund, LTD, Whitebox Special Opp Fund, LTD
	  		  	00001530	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	37,453	  	37,453
	 Wolverine Convertible Arbitrag, Wolverine Convertible Arbitrag
	  		  	00001472	  	9/29/2006	  	9/29/2011	  	3.32	  	$	2.750	  	376,344	  	376,344
	 Wolverine Convertible Arbitrag, Wolverine Convertible Arbitrag
	  		  	00001483	  	2/28/2007	  	2/28/2012	  	3.73	  	$	2.940	  	261,830	  	261,830
	 Wolverine Convertible Arbitrag, Wolverine Convertible Arbitrag
	  		  	00001531	  	10/19/2007	  	1/19/2009	  	0.62	  	$	2.670	  	193,820	  	193,820
	TOTALS	  		  		  		  		  		  			  	20,824,000	  	20,674,000

									
	Accentia Biopharmaceuticals, Inc.	  	OUTSTANDING AND EXERCISABLE BY PRICE	  		  	Page:	  	1
		  	AS OF 6/6/2008	  		  	File:	  	Osprice
		  	Plan is equal to acct	  		  	Date:	  	6/12/2008
		  		  		  	Time:	  	3:44:23 PM

  

																		
	 Name
	  	 ID
	  	 Number
	  	 Option
Date
	  	 Expiration
Date
	  	 Remaining
Life in Years
	  	Option
Price	  	 Shares
Outstanding
	  	 Shares
Exercisable

	 Sorenson, Fred
	  		  	00000647	  	12/1/2003	  	12/1/2013	  	5.49	  	$	5.15	  	84,956	  	84,956
	 Bergemman, Rito
	  		  	00000648	  	12/1/2003	  	12/1/2013	  	5.49	  	$	5.15	  	84,956	  	84,956
	 Birdsong, David A.
	  		  	00000143	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	226	  	226
	 Birdsong, David A.
	  		  	00000144	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	1,576	  	1,576
	 Birdsong, David A.
	  		  	00000145	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	45	  	45
	 Birdsong, David A.
	  		  	00000659	  	1/1/2004	  	1/1/2014	  	5.57	  	$	4.45	  	225	  	225
	 Birdsong, David A.
	  		  	00000146	  	5/9/2003	  	5/9/2013	  	4.92	  	$	2.22	  	675	  	675
	 Born, Randall E.
	  		  	00000152	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	563	  	563
	 Born, Randall E.
	  		  	00000153	  	5/9/2003	  	5/9/2013	  	4.92	  	$	2.22	  	338	  	338
	 Butler, Jim (James)
	  		  	00000120	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 Denovchek, Stephen M.
	  		  	00000180	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,252	  	2,252
	 Denovchek, Stephen M.
	  		  	00000181	  	5/9/2003	  	5/9/2013	  	4.92	  	$	2.22	  	675	  	675
	 Diesbach, Lawrence
	  		  	00000182	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	158	  	158
	 Disbrow, Cliff
	  		  	00000183	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 Holt, David
	  		  	00000586	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,072	  	2,072
	 Johnson, Ross M.
	  		  	00000209	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,252	  	2,252
	 Jones, Dudley (Rick) R.
	  		  	00000210	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,252	  	2,252
	 Jones, Dudley (Rick) R.
	  		  	00000211	  	5/9/2003	  	5/9/2013	  	4.92	  	$	2.22	  	675	  	675
	 Mario, Ernest
	  		  	00000253	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 Marro, Edward P.
	  		  	00000254	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 Navarro, Robert
	  		  	00000265	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 O’Donnell, Francis E. (Accentia)
	  		  	00000270	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,252	  	2,252
	 Reynolds, William C.
	  		  	00000283	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	1,576	  	1,576
	 Reynolds, William C.
	  		  	00000424	  	11/7/2003	  	11/7/2013	  	5.42	  	$	4.45	  	675	  	675
	 Reynolds, William C.
	  		  	00000284	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	675	  	675
	 Stefano, Steve
	  		  	00000290	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	2,252	  	2,252
	 Stewart, Jim
	  		  	00000291	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	450	  	450
	 Thomas, II, William J.
	  		  	00000293	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	6,755	  	6,755
	 Whitaker, Trampas
	  		  	00000295	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	180	  	180
	 Yurick, Gregory A.
	  		  	00000247	  	5/9/2003	  	5/9/2013	  	4.92	  	$	2.22	  	338	  	338
	 Yurick, Gregory A.
	  		  	00000302	  	4/10/2003	  	4/10/2013	  	4.84	  	$	2.22	  	563	  	563
	 Alexandrescu, Kimberly
	  		  	00001609	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Arikian, Steven R.(accentia)
	  		  	00000305	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	95,012	  	95,012
	 Arikian, Steven R.(accentia)
	  		  	00001645	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	100,000	  	33,334
	 Arikian, Steven R.(accentia)
	  		  	00001686	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	30,000	  	0
	 Arora, Sarika
	  		  	00001652	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334
	 Baker, David
	  		  	00001602	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667
	 Bathen, Kristin
	  		  	00001188	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	11	  	11
	 Bathen, Kristin
	  		  	00001258	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	275	  	275
	 Bathen, Kristin
	  		  	00001317	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	275	  	184
	 Berenson, Karina L.
	  		  	00001242	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,740	  	2,740
	 Berenson, Karina L.
	  		  	00001301	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,740	  	1,827
	 Berenson, Karina L.
	  		  	00001552	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 Birdsong, David A.
	  		  	00001363	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	667	  	667
	 Birdsong, David A.
	  		  	00001124	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,700	  	2,700
	 Birdsong, David A.
	  		  	00001347	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	6,479	  	6,479
	 Birdsong, David A.
	  		  	00001288	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,283	  	2,283
	 Birdsong, David A.
	  		  	00000958	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	1,900	  	1,900
	 Birdsong, David A.
	  		  	00001550	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	6,667	  	6,667

																		
	 Birdsong, David A.
	 		  	00001656	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	334	  	334
	 Birdsong, David A.
	 		  	00000309	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	1,425	  	1,425
	 Birdsong, David A.
	 		  	00000897	  	8/9/2004	  	8/9/2014	  	6.18	  	$	3.160	  	2,375	  	2,375
	 Blaes, Barbara A
	 		  	00000898	  	7/6/2004	  	7/6/2014	  	6.08	  	$	2.630	  	950	  	950
	 Blaes, Barbara A
	 		  	00001654	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	167
	 Blaes, Barbara A
	 		  	00001557	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	10,000	  	3,334
	 Blanco, Lauren
	 		  	00001588	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Bonitz, Susan
	 		  	00001512	  	6/4/2007	  	6/4/2017	  	8.99	  	$	2.900	  	15,000	  	10,000
	 Bonitz, Susan
	 		  	00001658	  	1/28/2008	  	1/28/2018	  	9.65	  	$	2.580	  	15,000	  	5,000
	 Born, Randall E.
	 		  	00000961	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	143	  	143
	 Born, Randall E.
	 		  	00001125	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	900	  	900
	 Born, Randall E.
	 		  	00001570	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Bottjer, Brian D
	 		  	00001519	  	7/10/2007	  	7/10/2017	  	9.09	  	$	2.790	  	5,000	  	1,667
	 Bottjer, Brian D
	 		  	00001564	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 Breuer, Thomas
	 		  	00001189	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	704	  	704
	 Breuer, Thomas
	 		  	00001255	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,651	  	1,651
	 Breuer, Thomas
	 		  	00001314	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,651	  	1,101
	 Brockmeier, Birgit
	 		  	00001190	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	364	  	364
	 Brockmeier, Birgit
	 		  	00001259	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	254	  	254
	 Brockmeier, Birgit
	 		  	00001318	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	254	  	170
	 Calder, Douglas
	 		  	00001541	  	11/29/2007	  	11/29/2017	  	9.48	  	$	2.700	  	15,000	  	0
	 Caravello, Jessica
	 		  	00001603	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Casciano, Roman N.
	 		  	00000589	  	10/23/2002	  	10/23/2012	  	4.38	  	$	2.110	  	23,753	  	23,753
	 Casciano, Roman N.
	 		  	00001544	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	75,000	  	25,000
	 Casciano, Roman N.
	 		  	00001409	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	8,549	  	5,700
	 Casciano, Roman N.
	 		  	00001391	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	8,549	  	8,549
	 Casciano, Roman N.
	 		  	00000904	  	3/1/2004	  	3/1/2014	  	5.73	  	$	2.630	  	23,753	  	23,753
	 Casciano, Roman N.
	 		  	00001171	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	7,401	  	7,401
	 Chapman, Christopher C
	 		  	00001694	  	4/16/2008	  	4/16/2018	  	9.86	  	$	0.810	  	52,500	  	0
	 Chuklavit, Maruit Jonathan
	 		  	00001618	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334
	 Clary, Tyrisha M.
	 		  	00001610	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334
	 Cohen, Carl M.
	 		  	00000905	  	11/19/2004	  	11/19/2014	  	6.45	  	$	3.160	  	35,629	  	35,629
	 Coleman, Vance M.
	 		  	00000906	  	10/4/2004	  	10/4/2014	  	6.33	  	$	3.160	  	950	  	950
	 Coleman, Vance M.
	 		  	00001559	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	10,000	  	3,334
	 Consiglieri , Romulo
	 		  	00000807	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	225	  	225
	 Consiglieri , Romulo
	 		  	00001179	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,644	  	1,644
	 Consiglieri , Romulo
	 		  	00001285	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,468	  	1,468
	 Consiglieri , Romulo
	 		  	00001344	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,468	  	979
	 Costello, Vicki
	 		  	00001419	  	12/15/2006	  	12/15/2016	  	8.53	  	$	2.310	  	1,666	  	1,666
	 Costello, Vicki
	 		  	00001589	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,667	  	1,667
	 Crofts, Karen (KC)
	 		  	00001606	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Cross, Brian W.
	 		  	00001385	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	3,262	  	3,262
	 Cross, Brian W.
	 		  	00001402	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	3,262	  	2,175
	 Cross, Brian W.
	 		  	00001222	  	2/9/2006	  	2/9/2016	  	7.68	  	$	8.000	  	5,000	  	5,000
	 Cross, Brian W.
	 		  	00001152	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	374	  	374
	 Cross, Brian W.
	 		  	00001554	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 Daniel, Lora
	 		  	00000324	  	2/17/2004	  	2/17/2014	  	5.70	  	$	2.630	  	950	  	950
	 Daniel, Lora
	 		  	00001576	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Demmig, Susanne
	 		  	00000787	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	319	  	319
	 Demmig, Susanne
	 		  	00001319	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	102	  	69
	 Demmig, Susanne
	 		  	00001204	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	169	  	169
	 Demmig, Susanne
	 		  	00001260	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	102	  	102
	 Denovchek, Stephen M.
	 		  	00000327	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	1,188	  	1,188
	 Denovchek, Stephen M.
	 		  	00000969	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	950	  	950
	 Denovchek, Stephen M.
	 		  	00001220	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,900	  	2,900
	 Denovchek, Stephen M.
	 		  	00001436	  	3/5/2007	  	3/5/2017	  	8.75	  	$	3.570	  	5,000	  	1,666
	 Denovchek, Stephen M.
	 		  	00001655	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334

																		
	 Denovchek, Stephen M.
	  		  	00001561	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	10,000	  	3,334
	 Denovchek, Stephen M.
	  		  	00001362	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,000	  	667
	 Dolgitser, Margarita
	  		  	00001434	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,142	  	762
	 Dolgitser, Margarita
	  		  	00001435	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,142	  	1,142
	 Dolgitser, Margarita
	  		  	00001566	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667
	 Doron, Krista
	  		  	00001096	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,000	  	2,000
	 Dubinsky, John P.
	  		  	00001216	  	11/2/2005	  	11/2/2015	  	7.41	  	$	8.000	  	30,000	  	30,000
	 Dubinsky, John P.
	  		  	00001637	  	3/1/2007	  	3/1/2017	  	8.73	  	$	3.620	  	15,000	  	15,000
	 Duffey, Samuel S. (Accentia)
	  		  	00000330	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	118,765	  	118,765
	 Duffey, Samuel S. (Accentia)
	  		  	00001146	  	2/9/2006	  	2/9/2016	  	7.68	  	$	7.590	  	41,168	  	41,168
	 Duffey, Samuel S. (Accentia)
	  		  	00001380	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	41,168	  	41,168
	 Duffey, Samuel S. (Accentia)
	  		  	00001375	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	345,257	  	230,173
	 Duffey, Samuel S. (Accentia)
	  		  	00001374	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	4,743	  	3,159
	 Duffey, Samuel S. (Accentia)
	  		  	00001641	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	74,349	  	1
	 Duffey, Samuel S. (Accentia)
	  		  	00001642	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	200,651	  	91,666
	 Duffy, Kristy D
	  		  	00001657	  	2/4/2008	  	2/4/2018	  	9.67	  	$	2.940	  	10,000	  	0
	 Faerber, Janice
	  		  	00001427	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,200	  	1,200
	 Faerber, Janice
	  		  	00001428	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,200	  	801
	 Faerber, Janice
	  		  	00001578	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Flores, Melissa
	  		  	00001630	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Frederick, Argelis
	  		  	00001628	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Freivogel , Klaus
	  		  	00000782	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	417	  	417
	 Freivogel , Klaus
	  		  	00001180	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,516	  	1,516
	 Freivogel , Klaus
	  		  	00001320	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	412	  	275
	 Freivogel , Klaus
	  		  	00001261	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	412	  	412
	 Fuhr, Katharina
	  		  	00000785	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	354	  	354
	 Fuhr, Katharina
	  		  	00001181	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,225	  	1,225
	 Fuhr, Katharina
	  		  	00001345	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	500	  	334
	 Fuhr, Katharina
	  		  	00001286	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	500	  	500
	 Gaughan, Matthew C.
	  		  	00001595	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 George, Megan
	  		  	00001622	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Gibson, Elizabeth
	  		  	00000336	  	1/12/2004	  	1/12/2014	  	5.60	  	$	2.630	  	950	  	950
	 Gibson, Elizabeth
	  		  	00001575	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,000	  	1,000
	 Glass, Jared
	  		  	00001626	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Glover, Shelly L.
	  		  	00001099	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,000	  	2,000
	 Glover, Shelly L.
	  		  	00001581	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Gossage, Teresa C.
	  		  	00001148	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	319	  	319
	 Gossage, Teresa C.
	  		  	00001591	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Gossage, Teresa C.
	  		  	00001386	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,631	  	1,631
	 Gossage, Teresa C.
	  		  	00001403	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,631	  	1,088
	 Gowen, Andrew C.
	  		  	00001599	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Greger , Astrid
	  		  	00000788	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	413	  	413
	 Greger , Astrid
	  		  	00001191	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	374	  	374
	 Greger , Astrid
	  		  	00001321	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	164	  	110
	 Greger , Astrid
	  		  	00001262	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	164	  	164
	 Groß, Sonja
	  		  	00000794	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	496	  	496
	 Groß, Sonja
	  		  	00001322	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	309	  	207
	 Groß, Sonja
	  		  	00001369	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	419	  	419
	 Groß, Sonja
	  		  	00001368	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	309	  	309
	 Gultyaev , Dmitry
	  		  	00001264	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,338	  	1,338
	 Gultyaev , Dmitry
	  		  	00001206	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	643	  	643
	 Gultyaev , Dmitry
	  		  	00000805	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	455	  	455
	 Gultyaev , Dmitry
	  		  	00001323	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,338	  	893
	 Hammer, Martin
	  		  	00000594	  	3/31/2004	  	3/31/2014	  	5.82	  	$	2.630	  	17,518	  	17,518
	 Hasara, Garrison (acct)
	  		  	00000885	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	4,751	  	4,751
	 Hasara, Garrison (acct)
	  		  	00001383	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	9,786	  	9,786
	 Hasara, Garrison (acct)
	  		  	00001422	  	10/10/2006	  	10/10/2016	  	8.35	  	$	2.440	  	20,000	  	13,334

																		
	 Hasara, Garrison (acct)
	 		  	00001640	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	12,251	  	12,251
	 Hasara, Garrison (acct)
	 		  	00001639	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	87,749	  	21,083
	 Hasara, Garrison (acct)
	 		  	00001400	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	9,786	  	6,525
	 Hasara, Garrison (acct)
	 		  	00001153	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	6,986	  	6,986
	 Hassel, Benedikt
	 		  	00001213	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,300	  	1,300
	 Hatchett, Krista D.
	 		  	00001593	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Himmelsbach, Diana
	 		  	00001193	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	225	  	225
	 Himmelsbach, Diana
	 		  	00001325	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	206	  	138
	 Himmelsbach, Diana
	 		  	00001266	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	206	  	206
	 Hittinger, Michael W.
	 		  	00001598	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Hoffmann, Jonas
	 		  	00000784	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	198	  	198
	 Hoffmann, Jonas
	 		  	00001175	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	108	  	108
	 Hoffmann, Jonas
	 		  	00001267	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	176	  	176
	 Hoffmann, Jonas
	 		  	00001326	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	176	  	118
	 Houston, Michael
	 		  	00001616	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Hoyt, Morgan Leigh
	 		  	00001627	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Hussey, Joanne
	 		  	00001394	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,936	  	2,936
	 Hussey, Joanne
	 		  	00001412	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,936	  	1,958
	 Hussey, Joanne
	 		  	00001586	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Jaffee, Margo
	 		  	00001520	  	9/14/2007	  	9/14/2017	  	9.27	  	$	3.790	  	1,000	  	334
	 Jaffee, Margo
	 		  	00001635	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,000	  	667
	 Jakob, Waltraud
	 		  	00000789	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	342	  	342
	 Jakob, Waltraud
	 		  	00001268	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	154	  	154
	 Jakob, Waltraud
	 		  	00001327	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	154	  	103
	 Jakob, Waltraud
	 		  	00001194	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	380	  	380
	 Johnson, YiYi Lam
	 		  	00001424	  	10/10/2006	  	10/10/2016	  	8.35	  	$	2.440	  	7,500	  	5,000
	 Johnson, YiYi Lam
	 		  	00001585	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	7,500	  	2,500
	 Johnson, YiYi Lam
	 		  	00001387	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	897	  	897
	 Johnson, YiYi Lam
	 		  	00001404	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	897	  	599
	 Jones, Dudley (Rick) R.
	 		  	00000349	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	1,188	  	1,188
	 Jones, Dudley (Rick) R.
	 		  	00000916	  	8/9/2004	  	8/9/2014	  	6.18	  	$	3.160	  	2,375	  	2,375
	 Jones, Dudley (Rick) R.
	 		  	00001134	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,900	  	2,900
	 Jones, Dudley (Rick) R.
	 		  	00001348	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	8,834	  	5,890
	 Jones, Dudley (Rick) R.
	 		  	00001545	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	50,000	  	16,667
	 Jones, Dudley (Rick) R.
	 		  	00001430	  	3/8/2007	  	3/8/2017	  	8.75	  	$	3.530	  	15,000	  	5,000
	 Jones, Dudley (Rick) R.
	 		  	00001289	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	3,262	  	3,262
	 Jones, Dudley (Rick) R.
	 		  	00000980	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	1,900	  	1,900
	 Kalpas, Edward A.
	 		  	00001632	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	667	  	667
	 Kempf-Müller , Dr. Andrea
	 		  	00000793	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	292	  	292
	 Kempf-Müller , Dr. Andrea
	 		  	00001269	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	145	  	145
	 Kempf-Müller , Dr. Andrea
	 		  	00001328	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	145	  	97
	 Kempf-Müller , Dr. Andrea
	 		  	00001207	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	242	  	242
	 Kennemer, Erin E.
	 		  	00001612	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 King, Edmund C.
	 		  	00001229	  	10/27/2006	  	10/27/2016	  	8.39	  	$	3.170	  	35,000	  	23,333
	 King, Edmund C.
	 		  	00001689	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	60,000	  	0
	 Kiss, Maria
	 		  	00000800	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	315	  	315
	 Kiss, Maria
	 		  	00001270	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	73	  	73
	 Kiss, Maria
	 		  	00001329	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	73	  	49
	 Kleiss, David
	 		  	00001629	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Klemm, Stephan
	 		  	00000895	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	432	  	432
	 Klemm, Stephan
	 		  	00001208	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	513	  	513
	 Klemm, Stephan
	 		  	00001330	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	305	  	204
	 Klemm, Stephan
	 		  	00001271	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	305	  	305
	 Krakus, Michelle R.
	 		  	00001166	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	527	  	527
	 Krone, Frank
	 		  	00001650	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	10,000	  	3,334
	 Krukas, Michelle R.
	 		  	00001246	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,009	  	2,009
	 Krukas, Michelle R.
	 		  	00001580	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667

  

																		
	 Krukas, Michelle R.
	 		  	00001305	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,009	  	1,340
	 Kuckuk, Thomas
	 		  	00000781	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	794	  	794
	 Kwok, Annis
	 		  	00001395	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	456	  	456
	 Kwok, Annis
	 		  	00001413	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	456	  	305
	 Kwok, Annis
	 		  	00001584	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Ladwig, Glenn P.
	 		  	00001542	  	11/29/2007	  	11/29/2017	  	9.48	  	$	2.700	  	20,000	  	0
	 Liczencias, Erika
	 		  	00001176	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	162	  	162
	 Liczencias, Erika
	 		  	00001331	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	587	  	392
	 Liczencias, Erika
	 		  	00001272	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	587	  	587
	 Lipp, David C.
	 		  	00000362	  	11/7/2003	  	11/7/2013	  	5.42	  	$	1.050	  	1,188	  	1,188
	 Lipp, David C.
	 		  	00001573	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Lipp, David C.
	 		  	00000986	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	143	  	143
	 Little, Stephen D.
	 		  	00001625	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Ludwig, Anna
	 		  	00001273	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	51	  	51
	 Ludwig, Anna
	 		  	00001332	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	51	  	35
	 Machado, Manuel
	 		  	00001174	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,691	  	1,691
	 Machado, Manuel
	 		  	00001571	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667
	 Machado, Manuel
	 		  	00001247	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	920	  	920
	 Machado, Manuel
	 		  	00001306	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	920	  	614
	 Marshall, Rob
	 		  	00001693	  	3/17/2008	  	3/17/2018	  	9.78	  	$	2.730	  	10,000	  	0
	 Martinez, Jr., Alejandro (Alex)
	 		  	00001619	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Matthews, Norman (Max)
	 		  	00001605	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 McLendon, Gypsy L
	 		  	00000925	  	4/26/2004	  	4/26/2014	  	5.89	  	$	2.630	  	950	  	950
	 McLeod, Carroll
	 		  	00001008	  	4/8/2004	  	4/8/2014	  	5.84	  	$	2.630	  	1,900	  	1,900
	 McNulty, James (acct)
	 		  	00000643	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	118,765	  	118,765
	 McNulty, James (acct)
	 		  	00001145	  	2/9/2006	  	2/9/2016	  	7.68	  	$	7.590	  	25,449	  	25,449
	 McNulty, James (acct)
	 		  	00001372	  	12/20/2006	  	12/20/2016	  	8.54	  	$	3.560	  	25,600	  	12,800
	 McNulty, James (acct)
	 		  	00001371	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	12,337	  	12,337
	 McNulty, James (acct)
	 		  	00001370	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	13,112	  	13,112
	 McNulty, James (acct)
	 		  	00001373	  	12/20/2006	  	12/20/2016	  	8.54	  	$	3.560	  	124,400	  	87,206
	 McNulty, James (acct)
	 		  	00001647	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	100,652	  	58,334
	 McNulty, James (acct)
	 		  	00001646	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	74,348	  	0
	 McNulty, William J.
	 		  	00001156	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	3,992	  	3,992
	 McNulty, William J.
	 		  	00001548	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 McNulty, William J.
	 		  	00001384	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	10,439	  	10,439
	 McNulty, William J.
	 		  	00001006	  	3/1/2004	  	3/1/2014	  	5.73	  	$	2.630	  	11,876	  	11,876
	 McNulty, William J.
	 		  	00000890	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	4,751	  	4,751
	 McNulty, William J.
	 		  	00001401	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	10,439	  	6,960
	 McOmber, Ben
	 		  	00001604	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Mermejean, Patricia
	 		  	00001195	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	772	  	772
	 Morlotti, Luca
	 		  	00001177	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	108	  	108
	 Moser, David D
	 		  	00001551	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	50,000	  	16,667
	 Mueller , Elvira
	 		  	00000801	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	808	  	808
	 Mueller , Elvira
	 		  	00001648	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 Mueller , Elvira
	 		  	00001316	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,827	  	1,885
	 Mueller , Elvira
	 		  	00001218	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	2,598	  	2,598
	 Mueller , Elvira
	 		  	00001257	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,827	  	2,827
	 Müller-Welte , Inka
	 		  	00000791	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	326	  	326
	 Neumann, Monika
	 		  	00000810	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	361	  	361
	 Neumann, Monika
	 		  	00001333	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	811	  	541
	 Neumann, Monika
	 		  	00001196	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	696	  	696
	 Neumann, Monika
	 		  	00001274	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	811	  	811
	 O’Donnell, Francis E. (Accentia)
	 		  	00001690	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	37,500	  	0
	 Ogbonnaya, Augustina
	 		  	00001614	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334
	 Parker, Beverly D.
	 		  	00001108	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,000	  	2,000
	 Parker, Beverly D.
	 		  	00001590	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Paschall, Pamela G.
	 		  	00001431	  	3/12/2007	  	3/12/2017	  	8.76	  	$	3.550	  	5,000	  	1,666

																		
	 Paschall, Pamela G.
	  		  	00001562	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	12,500	  	4,167
	 Pasquale, Carmen
	  		  	00000799	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	311	  	311
	 Pasquale, Carmen
	  		  	00001334	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	587	  	392
	 Pasquale, Carmen
	  		  	00001183	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,183	  	1,183
	 Pasquale, Carmen
	  		  	00001275	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	587	  	587
	 Paul, Renee
	  		  	00001563	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	15,000	  	5,000
	 Paul, Renee
	  		  	00001405	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,957	  	1,305
	 Paul, Renee
	  		  	00001388	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,957	  	1,957
	 Paul, Renee
	  		  	00001157	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	898	  	898
	 Paul, Renee
	  		  	00001149	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	998	  	998
	 Paul, Renee
	  		  	00000887	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	1,900	  	1,900
	 Pearce, Alan M.
	  		  	00001147	  	2/9/2006	  	2/9/2016	  	7.68	  	$	7.590	  	37,425	  	37,425
	 Pearce, Alan M.
	  		  	00001378	  	12/20/2006	  	12/20/2016	  	8.54	  	$	3.560	  	8,600	  	4,299
	 Pearce, Alan M.
	  		  	00001379	  	12/20/2006	  	12/20/2016	  	8.54	  	$	3.560	  	241,400	  	162,375
	 Pearce, Alan M.
	  		  	00001643	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	200,652	  	91,667
	 Pearce, Alan M.
	  		  	00001692	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	30,000	  	0
	 Pearce, Alan M.
	  		  	00001644	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	74,348	  	0
	 Pearce, Alan M.
	  		  	00001636	  	2/9/2006	  	2/9/2016	  	7.68	  	$	7.590	  	47,431	  	47,431
	 Pearce, Alan M.
	  		  	00001376	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	4,137	  	4,137
	 Pearce, Alan M.
	  		  	00001377	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.700	  	33,288	  	33,288
	 Perrie, Nickie
	  		  	00000934	  	8/11/2004	  	8/11/2014	  	6.18	  	$	3.160	  	475	  	475
	 Plaza, Douglas A.
	  		  	00000891	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	1,188	  	1,188
	 Plaza, Douglas A.
	  		  	00001407	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,398	  	2,398
	 Plaza, Douglas A.
	  		  	00001555	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,334	  	3,334
	 Plaza, Douglas A.
	  		  	00001389	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	3,596	  	3,596
	 Plaza, Douglas A.
	  		  	00001007	  	3/1/2004	  	3/1/2014	  	5.73	  	$	2.630	  	7,126	  	7,126
	 Plaza, Douglas A.
	  		  	00001155	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	2,994	  	2,994
	 Podoloff, Colea
	  		  	00001633	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Poole, William
	  		  	00001537	  	6/25/2007	  	6/25/2017	  	9.05	  	$	3.060	  	20,000	  	6,666
	 Poole, William
	  		  	00001691	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	45,000	  	0
	 Powers, Debra
	  		  	00001634	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Precht, Christy R.
	  		  	00000935	  	8/23/2004	  	8/23/2014	  	6.21	  	$	3.160	  	950	  	950
	 Priebe, Barbara
	  		  	00000796	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	404	  	404
	 Priebe, Barbara
	  		  	00001276	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	792	  	792
	 Priebe, Barbara
	  		  	00001335	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	792	  	529
	 Priebe, Barbara
	  		  	00001197	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	467	  	467
	 Rains, Manfred
	  		  	00001433	  	12/15/2006	  	12/15/2016	  	8.53	  	$	8.510	  	4,750	  	4,750
	 Reynolds, William C.
	  		  	00001560	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	4,167	  	4,167
	 Reynolds, William C.
	  		  	00001356	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,001	  	1,001
	 Reynolds, William C.
	  		  	00001297	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	500	  	500
	 Reynolds, William C.
	  		  	00001119	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,900	  	2,900
	 Reynolds, William C.
	  		  	00000997	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	1,259	  	1,259
	 Reynolds, William C.
	  		  	00000125	  	4/10/2003	  	4/10/2013	  	4.84	  	$	1.050	  	1,663	  	1,663
	 Roberts, Douglas F
	  		  	00000937	  	7/6/2004	  	7/6/2014	  	6.08	  	$	2.630	  	2,850	  	2,850
	 Roberts, Douglas F
	  		  	00001558	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,334	  	3,334
	 Roos, Stacy
	  		  	00001596	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Rosengarten, Mark
	  		  	00001521	  	9/21/2007	  	9/21/2017	  	9.29	  	$	3.220	  	3,334	  	3,334
	 Rosengarten, Mark
	  		  	00001549	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	5,000
	 Rosery, Hubertus
	  		  	00000804	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	390	  	390
	 Rosery, Hubertus
	  		  	00001209	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	674	  	674
	 Rushworth, Alison
	  		  	00000797	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	270	  	270
	 Rushworth, Alison
	  		  	00001210	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	254	  	254
	 Rushworth, Alison
	  		  	00001336	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	152	  	102
	 Rushworth, Alison
	  		  	00001277	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	152	  	152
	 Ryll, Dennis
	  	(DG)	  	00000845	  	4/16/2004	  	4/16/2014	  	5.86	  	$	2.110	  	5,938	  	5,938
	 Salyers, Chapelle
	  		  	00001607	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Santos, Carlos
	  		  	00001426	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,174	  	1,174

																		
	 Santos, Carlos
	 		  	00001572	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667
	 Santos, Carlos
	 		  	00001429	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,174	  	783
	 Scheer, Linda M.
	 		  	00001111	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	2,000	  	2,000
	 Scheer, Linda M.
	 		  	00001582	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Schiller, Ilona
	 		  	00000798	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	374	  	374
	 Schiller, Ilona
	 		  	00001198	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	610	  	610
	 Schmidt , Elvira
	 		  	00000802	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	493	  	493
	 Schmidt , Elvira
	 		  	00001278	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,584	  	1,584
	 Schmidt , Elvira
	 		  	00001337	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,584	  	1,057
	 Schmidt , Elvira
	 		  	00001184	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,668	  	1,668
	 Schmidt, Anke
	 		  	00001192	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	723	  	723
	 Schmidt, Anke
	 		  	00001324	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	705	  	471
	 Schmidt, Anke
	 		  	00001265	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	705	  	705
	 Schraibman, Eric
	 		  	00000390	  	1/26/2004	  	1/26/2014	  	5.64	  	$	2.630	  	950	  	950
	 Schraibman, Eric
	 		  	00001651	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Schreiner , Raphaela
	 		  	00000786	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	376	  	376
	 Schreiner , Raphaela
	 		  	00001338	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	287	  	192
	 Schreiner , Raphaela
	 		  	00001279	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	287	  	287
	 Schreiner , Raphaela
	 		  	00001185	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	972	  	972
	 Schubert, David M.
	 		  	00001638	  	3/1/2007	  	3/1/2017	  	8.73	  	$	3.620	  	40,000	  	13,334
	 Schubert, David M.
	 		  	00001687	  	2/29/2008	  	3/1/2018	  	9.73	  	$	2.610	  	52,500	  	0
	 Schubert, David M.
	 		  	00001215	  	11/2/2005	  	11/2/2015	  	7.41	  	$	8.000	  	35,000	  	23,333
	 Schwander, Björn
	 		  	00000803	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	355	  	355
	 Schwander, Björn
	 		  	00001199	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	678	  	678
	 Schwander, Björn
	 		  	00001339	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,188	  	793
	 Schwander, Björn
	 		  	00001280	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,188	  	1,188
	 Sellen , Kirsten
	 		  	00000795	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	511	  	511
	 Sellen , Kirsten
	 		  	00001340	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	407	  	272
	 Sellen , Kirsten
	 		  	00001281	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	407	  	407
	 Sellen , Kirsten
	 		  	00001186	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,641	  	1,641
	 Sewell, John M.
	 		  	00001224	  	2/9/2006	  	2/9/2016	  	7.68	  	$	8.000	  	3,000	  	3,000
	 Sewell, John M.
	 		  	00001406	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,305	  	871
	 Sewell, John M.
	 		  	00001583	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Sewell, John M.
	 		  	00001421	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	1,305	  	1,305
	 Sorenson, Fred
	 		  	00001214	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	2,166	  	2,166
	 Sorenson, Fred
	 		  	00001649	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	30,000	  	10,000
	 Soto, Cynthia
	 		  	00001617	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Stergiou, Angelos
	 		  	00001172	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	6,036	  	6,036
	 Stergiou, Angelos
	 		  	00001221	  	2/9/2006	  	2/9/2016	  	7.68	  	$	8.000	  	5,000	  	3,333
	 Stergiou, Angelos
	 		  	00001393	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	5,480	  	5,480
	 Stergiou, Angelos
	 		  	00001438	  	4/12/2007	  	4/12/2017	  	8.85	  	$	3.280	  	20,000	  	20,000
	 Stergiou, Angelos
	 		  	00001546	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	60,000	  	20,000
	 Stergiou, Angelos
	 		  	00001440	  	4/12/2007	  	4/12/2017	  	8.85	  	$	3.280	  	27,250	  	17,250
	 Stergiou, Angelos
	 		  	00001439	  	4/12/2007	  	4/12/2017	  	8.85	  	$	3.280	  	2,750	  	2,750
	 Stergiou, Angelos
	 		  	00001411	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	5,480	  	3,654
	 Stern , Lee
	 		  	00000637	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	26,603	  	26,603
	 Stern , Lee
	 		  	00000772	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	7,126	  	7,126
	 Stern , Lee
	 		  	00001162	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	6,198	  	6,198
	 Stern , Lee
	 		  	00001299	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	5,709	  	3,807
	 Stern , Lee
	 		  	00001547	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	30,000	  	10,000
	 Stern , Lee
	 		  	00001240	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	5,709	  	5,709
	 Stogel, Steven
	 		  	00001217	  	11/2/2005	  	11/2/2015	  	7.41	  	$	8.000	  	40,000	  	26,666
	 Stowe, Jr., Edward W.
	 		  	00000944	  	8/30/2004	  	8/30/2014	  	6.23	  	$	3.160	  	950	  	950
	 Stowe, Jr., Edward W.
	 		  	00001577	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,000	  	1,000
	 Subrahmanian, Tarun
	 		  	00001615	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Thieme , Marion
	 		  	00000792	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	420	  	420
	 Thieme , Marion
	 		  	00001200	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	809	  	809

																		
	 Thieme , Marion
	 		  	00001346	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	375	  	251
	 Thieme , Marion
	 		  	00001287	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	375	  	375
	 Thomas, II, William J.
	 		  	00000127	  	4/10/2003	  	4/10/2013	  	4.84	  	$	1.050	  	8,117	  	8,117
	 Thomas, II, William J.
	 		  	00001120	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	6,800	  	6,800
	 Trimpin, Jan
	 		  	00001178	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	108	  	108
	 Trinker, Debra L.
	 		  	00001623	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Tuberville, Johanna
	 		  	00000398	  	1/5/2004	  	1/5/2014	  	5.58	  	$	2.630	  	950	  	950
	 Tuberville, Johanna
	 		  	00001574	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Twohig, Katherine T.
	 		  	00001624	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Varshavsky, Tatyana
	 		  	00001249	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	685	  	685
	 Varshavsky, Tatyana
	 		  	00001308	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	685	  	457
	 Varshavsky, Tatyana
	 		  	00001568	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Vidal, Sasha F.
	 		  	00001250	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	428	  	428
	 Vidal, Sasha F.
	 		  	00001309	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	428	  	286
	 Vidal, Sasha F.
	 		  	00001587	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Vohringer, Cecilia
	 		  	00001201	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	218	  	218
	 Vohringer, Cecilia
	 		  	00001341	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	341	  	228
	 Vohringer, Cecilia
	 		  	00001282	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	341	  	341
	 Walls, Ramona
	 		  	00001611	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,000	  	334
	 Walusis, Jody
	 		  	00001621	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Walzer , Stefan
	 		  	00000806	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	200	  	200
	 Walzer , Stefan
	 		  	00001187	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,162	  	1,162
	 Watson, Sara
	 		  	00001613	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Wellmann, Birgit
	 		  	00001202	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	481	  	481
	 Wellmann, Birgit
	 		  	00001342	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	272	  	182
	 Wellmann, Birgit
	 		  	00001283	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	272	  	272
	 Whitaker, Ryan C.
	 		  	00001594	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,000	  	1,000
	 Whitmore, Jennifer
	 		  	00001620	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Wiederkeher, Daniel P
	 		  	00001167	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	1,090	  	1,090
	 Wiederkeher, Daniel P
	 		  	00001251	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,283	  	2,283
	 Wiederkeher, Daniel P
	 		  	00001310	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	2,283	  	1,523
	 Wiederkeher, Daniel P
	 		  	00001565	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,000	  	1,667
	 Wiles, Thomas
	 		  	00001631	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Wilmoth, Donna
	 		  	00001608	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	1,500	  	500
	 Wimbush, Alyson
	 		  	00001597	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	2,500	  	834
	 Worley, Angela
	 		  	00001601	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	500
	 Yousaf, Mehreen
	 		  	00001252	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	856	  	856
	 Yousaf, Mehreen
	 		  	00001311	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	856	  	571
	 Yousaf, Mehreen
	 		  	00001567	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	5,500	  	1,834
	 Yurick, Gregory A.
	 		  	00000407	  	11/7/2003	  	11/7/2013	  	5.42	  	$	2.110	  	143	  	143
	 Yurick, Gregory A.
	 		  	00001005	  	10/22/2004	  	10/22/2014	  	6.38	  	$	3.160	  	143	  	143
	 Yurick, Gregory A.
	 		  	00001144	  	1/1/2006	  	1/1/2016	  	7.57	  	$	8.000	  	900	  	900
	 Yurick, Gregory A.
	 		  	00001569	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	3,000	  	1,000
	 Yurick, Gregory A.
	 		  	00001653	  	1/7/2008	  	1/7/2018	  	9.59	  	$	2.690	  	500	  	167
	 Zerwes, Ute
	 		  	00000811	  	7/1/2004	  	7/1/2014	  	6.07	  	$	2.630	  	235	  	235
	 Zerwes, Ute
	 		  	00001203	  	2/9/2006	  	2/9/2016	  	7.68	  	$	6.900	  	518	  	518
	 Zerwes, Ute
	 		  	00001284	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	314	  	314
	 Zerwes, Ute
	 		  	00001343	  	12/15/2006	  	12/15/2016	  	8.53	  	$	3.360	  	314	  	210
		 		  		  		  		  		  			  	 	  	 
		 		  		  		  		  		  			  	4,315,358	  	2,547,929
		 		  		  		  		  		  			  	 	  	 

 Schedule 3.1(g)(ii) - Obligations of the Company to issue Common Stock - Adjustment in Conversion Price pursuant to
Section 4.18 
 The 8% Debentures financing dated September 29, 2006 (and related documents) 
 Midsummer Investment Ltd. 
 Whitebox Convertible Arbitrage, Ltd. 

Whitebox Hedged High Yield Partners 
 Guggenheim Portfolio 
 GPC LIX 
 Pandora Select Partners 
 Whitebox Intermarket Partners 
 Wolverine Convertible 
 Rockmore Investment 
 Laurus Master Fund 
 The 8% Debentures financing dated February 27, 2007 (and related documents) 
 Midsummer Investment Ltd. 
 Whitebox Convertible Arbitrage, Ltd. 
 Whitebox Hedged High Yield Partners 
 Guggenheim Portfolio 
 GPC LIX 
 Pandora Select Partners 
 Whitebox Intermarket Partners 
 Whitebx Special Opportunities Partners

 Wolverine Convertible 
 Rockmore Investment 
 UBS O’Connor LLC 
 BridgePointe Master Fund 
 GCA Strategic Fund 
 Diamond Opportunity Fund 
 Lloyd Miller 
 Crescent International 
 Cranshire Capital 
 R&R Opportunity Fund 
 The Convertible Preferred Stock financing dated January 18, 2008 (and related documents) 
 Valens U.S. SPV I, LLC 
 Valens Offshore SPV I, Ltd. 
 BAM Opportunity Fund LP 
 Hudson Bay Fund, LP 
 Hudson Bay Overseas Fund, Ltd 
 RRC Bio Fund, LP 
 Cranshire Capital, L.P. 
 Rosalind Capital Partners L.P. 
 Biohedge Holdings Limited 
 Diamond Opportunity Fund, LLC 
 Rockmore Investment Master Fund, Ltd. 
 BridgePointe Master Fund, Ltd. 
 GCA Strategic Investment Fund Limited 

 The following authorizations are required for the issuance of the Securities: 
 Board of Directors’ authorization 

 Schedule 3.1(i) - Undisclosed Events 
 On June 17, 2008 the Company and Laurus Master fund, Ltd. (“Laurus”) entered into agreements (the
“Payoff and Amendment Agreements”) pursuant to which: (i) the Amended and Restated Secured Non-Convertible Revolving Note in the original principal amount of $5,000,000 dated as of April 29, 2005 (the “Revolving Note”)
was satisfied; (ii) the Second Amended and Restated Secured Convertible Minimum Borrowing Note in the original principal amount of $2,500,000 dated as of April 29, 2005 (the “Minimum Borrowing Note”) & Second Amended and
Restated Secured Convertible Term Note in the original principal amount of $5,000,000 dated as of April 29, 2005 (the “Term Note”) were modified to provided that no interest or principal would accrue or be paid until December 31,
2008 at which time the notes would be marked “Paid”, conditioned upon satisfaction of stated conditions; (iii) Laurus released its security interest in all assets of the company except the capital stock and assets of Analytica
International, Inc and the Company’s rights and interest in BiovaxID® royalties under the Royalty Agreement dated October 31, 2008; (iv) the Company agreed that if it sells
its Analytica subsidiary, it will pay all proceed to Laurus up to $8.8 million and all proceeds above $8.8 million will be equally shared between the Company and Laurus; (v) if the Company does not sell Analytica or other wise pay Laurus $8.8
million by December 31, 2008, the Company shall assign 2% royalty interest in BiovaxID from the Company’s royalty Agreement and Laurus may either (a) demand payment of the amount, (b) take ownership of Analytica in which instance
the Company will continue to be responsible for any deficit in the event Laurus sells Analytica, or (c) receive 1% royalty interest in BiovaxID worldwide sales from the Company’s royalty agreement for each $1 million of the amount then
remaining unpaid. 
 The other material terms and conditions of the agreements are as follows: 
  

	 	•	 	 The Company and Laurus have entered into an Assignment of Sale Proceeds whereby the Company has assigned to Laurus the proceeds of a contemplated sale of the
Company’s Analytica subsidiary, up to a total of $8.8 million, with the Company and Laurus equally dividing any proceeds of such a sale in excess of $8.8 million. This sale of Analytica (and/or cash payment in the amount of $8.8 million) is
required to occur on or before December 31, 2008. In the event that the Company does not sell Analytica by December 31, 2008, or if the sale proceeds are less than $8.8 million, the Company has the right to make cash payment to Laurus up
to the amount of the shortfall. In the event that the Company does not sell Analytica by December 31, 2008 or if the sale proceeds or other cash payments are less than $8.8 million, Laurus may seek the cash shortfall from Accentia, elect to
take possession of the stock of Analytica and the Company will continue to be obligated for any deficiency in the event Laurus sells Analytica, or to receive the assignment of additional royalty rights as described below.

  

	 	•	 	 The Company and Laurus have entered into an Assignment of Rights Under Royalty Agreement whereby the Company assigned to Laurus a royalty of 4% of worldwide sales
of BiovaxID reducing the Company’s royalty percentage in BiovaxID from 19.5% to 15.5%. The Assignment of Rights Under Royalty Agreement additionally provides for the potential of additional royalties which may be assigned to Laurus under
certain circumstances, including i) an additional assignment of 2% royalty in BiovaxID if no sale of Analytica takes place by December 31, 2008 or the Company does not otherwise make payment to Laurus of $8.8 million by that date; and ii) If
Analytica is not sold or payment of $8.8 million has not been made by December 31, 2008, Laurus has the option to elect to A) take possession of the stock of Analytica and look to the Company for any deficit resulting from a sale of Analytica
by Laurus; or B) receive an additional royalty in BiovaxID calculated on the basis of 1% of additional royalty for each $1 million shortfall in payment below $8.8 million (“Laurus’ Rights At December 31, 2008”).

  

	 	•	 	 The Company and Laurus have entered into a clarification of its existing guaranty obligation with respect to the outstanding Secured Promissory Note of Biovest to
Laurus to fix the amount guaranteed by the Company at $4.9 million. 

  

	 	•	 	 The Minimum Borrowing Note and the Term Note (the “Continuing Notes”) will continue in existence but are modified to provide that interest will not accrue
and no principal payment shall be required under the Continuing Notes until December 31, 2008, and to further clarify that any payment under the Continuing Notes will reduce the Company’s aggregate indebtedness to Laurus of $8.8 million
and will not alter or expand Laurus’ Rights at December 31, 2008 as described herein. 

  

	 	•	 	 Laurus’ right to convert amounts due under the Continuing Notes into common stock of the Company continues and the conversion price was reduced to $1.20 per
share. 

 The Company undertakes to provide an update to this disclosure in the event that any of the terms of this Laurus Debt Payoff and
Amendment transaction change in any material respect prior to the closing of the transaction. 

 Schedule 3.1(j) - Litigations 
 On April 3, 2008, the Financial Industry Regulatory Authority (FINRA) notified the Company of their review of
trading in the Company’s common stock surrounding the March 24, 2008 announcement of the results from the Phase 3 clinical trial of SinuNaseTM. FINRA’s review is still
ongoing. 

 Schedule 3.1(n) - Liens 
 Each of the Company’s subsidiaries and their assets are subject to a lien imposed by existing notes held by Laurus Master Fund, Ltd. 
 However, upon the closing of the Laurus Payoff Transaction, all of the Company’s subsidiaries and their assets will be released. Except for Analytica International, Inc.’s capital stock and assets and all of the Company’s
interest in the BiovaxID Royalty Agreement will be subject to a security interest granted to Laurus. Laurus will have the pre-emptive right to acquire the capital stock of Analytica. 
 Upon the closing of the Southwest Bank f/k/a Missouri State Bank Amendment to the Revolving Note Transaction, all of the Company’s subsidiaries and their assets used to secure the Southwest Revolving Note will be
released. Except for the inventory and accounts receivable of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals together with 15 million common stock shares of Biovest International, Inc. currently owned by the Company. 
 Upon the closing of the McKesson Corporation Amendment to the Termination Agreement Transaction, all of the Company’s subsidiaries and their assets used to secure
the McKesson transaction will be released. Except for the common stock shares of Biovest International, Inc. currently owned by the Company. 

 Schedule 3.1(q) - Transactions With Affiliates and Employees 
 None 

 Schedule 3.1(s) - Certain Fees 
 The Company shall pay to Rodman & Renshaw a cash placement fee (the “Placement Agent’s Fee”) equal to 7% of the aggregate purchase price paid by each purchaser of Securities that are placed in
the Offering. For clarification, no Placement Agent’s Fee shall be due or paid hereunder at the time of, or based on, warrant exercise or other convertible security conversion. 
 As additional compensation for the Services, the Company shall issue to Rodman or its designees at the closing of the Offering (the “Closing”), warrants (the “Rodman Warrants”) to purchase that
number of shares of common stock of the Company (“Shares”) equal to 5% of the aggregate number of Shares placed in the Offering, plus any Shares underlying any convertible Securities sold in the Offering, but excluding any warrants sold in
the Offering. The Rodman Warrants shall have the same terms, except any anti-dilution and other price adjustment terms, including exercise price (provided that it shall be at least 110% of the price at which Shares are issued to Investors) and
registration rights as the warrants issued to investors (“Investors”) in the Offering, subject to the requirements in respect of holding period required by NASD Rule 2710. If no warrants are issued to Investors, the Rodman Warrants shall
have an exercise price equal to 110% of the price at which Shares are issued to Investors, an exercise period of five years and registration rights for the Shares underlying the Rodman Warrants equivalent to those granted with respect to the Shares
and the holding period required by NASD Rule 2710. 

 SPA - Schedule 3.1(v) 
 REGISTRATION RIGHTS 
 as of June 6, 2008 
 Piggyback Registration Rights 
 Pursuant to a Registration Rights
Agreement, dated April 3, 2002, between the Company and Steven Arikian, M.D., John Doyle, Julian Casciano, and Roman Casciano, as amended by Amendment No. 1, dated March 30, 2005, and Amendment No. 2, dated April 29, 2005,
these four former stockholders of the Company’s Analytica subsidiary have piggyback registration rights under this agreement. 
 1.2
Company Registration. If the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public
offering of such securities solely for cash (otter than a registration relating solely to the sale of securities to participants in a Company stock plan, an offering or sale of securities pursuant to a Form S-4 (or successor form) registration
statement or a registration in which the only stock being registered is Common Stock issuable upon conversion of debt securities which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within twenty (20) days after giving of such notice by the Company, the Company shall, subject to the provisions of Section 1.7, cause to be registered under the Securities Act
all of the Registrable Securities that each such Holder has requested to be registered. 
 Under the Amended and Restated Investors’ Rights Agreement,
dated January 7, 2005, between the Company and Pharmaceutical Product Development, Inc., as amended July 8, 2005 and August 11, 2005, PPD has demand registration rights as to all of the shares of Common Stock held by it that were
issued upon the automatic conversion of the Company’s Series E Preferred Stock at the time of the Company’s IPO. 1,423,441 of such shares (out of a total of 4,270,323 registrable securities under such agreement) were included in the
Registration Statement effective on June 22, 2006. 
 1.3 Company Registration. If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities
solely for cash (other than a registration relating solely to the sate of securities to participants in a Company stock plan, or a registration on any form which does not include substantially the same information as would be required to be included
in a registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty (20) days
after mailing of written notice by the Company, the Company shall, subject to the provisions of Section 1.8, cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The
registration expenses of such withdrawn registration shall be borne by the Company in accordance with Section 1.7 hereof. 

 Under the Overadvance Letter Agreement, dated July 13, 2006, between the Company and Laurus Master Fund, Ltd.
(“Laurus”), the Company issued to Laurus 100,000 shares of Company common stock as a non-refundable servicing payment. Under this agreement, Laurus was granted piggyback registration rights as to future-filed resale registration
statements. 
 The Parent further agrees that if at any time after the date hereof there is not an effective Registration Statement covering
all of the Additional Shares issued hereunder and the Parent shall determine to prepare and file with the Securities and Exchange Commission a registration statement relating to an offering for its own account or the account of others under the
Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any
entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Parent shall send to Laurus written notice of such determination and, if within fifteen (15) days after receipt of such
notice, Laurus shall so request in writing, the Parent shall include in such registration statement all or any part of such Additional Shares Laurus requests to be registered, to the extent the Company may do so without violating registration rights
of others which exist as of the date of this Overadvance Side Letter, subject to customary underwriter cutbacks applicable to all holders of registration rights and subject to obtaining any required consent of any selling stockholders) to such
inclusion under such registration statement. 
 On June 15, 2007, the Company granted the following described warrants to certain related parties in
consideration for ongoing guarantees and asset pledges: 
 Warrants to purchase two million shares of the Company’s common stock to
Hopkins Capital Group II, LLC; Warrants to purchase two hundred thousand shares of the Company’s common stock to MOAB Investments, LP. Each of the warrants have an exercise period (“Term”) of four years from the date of grant. Each of
the warrants have an exercise price of $4.32 per share, which represents a 38% premium over the closing price of the Company’s common stock on the date of the grant of the warrants. The Warrants vested upon grant. The holders have limited
piggyback registration rights subject to the reasonable discretion of the Company. 
 (d) Piggyback Registration Rights. In the event
that the Company plans to file a registration statement with, the U. S. Securities and Exchange Commission covering shares of common stock of the Company (“Registration Statement”), the Company shall provide written notice to Holder and
Holder shall have 30 days to require in writing that all shares of common stock underlying the Warrant, to the extent vested, be covered in the Registration Statement. Notwithstanding the foregoing, the Company shall have full discretion to
determine not to include the shares underlying the warrant in any registration statement if the Company reasonably determines that such registration may adversely effect the registration statement, the offering described in the registration
statement or otherwise adversely affect the Company. 

 On October 19, 2007, the Company issued warrants to certain of the investors in the February 28, 2007 8%
Convertible Debenture Financing to purchase up to 1,895,133 shares of the Company’s Common Stock with an exercise price of $2.67 per share and with a term expiring on the first to occur of January 19, 2009 or three days following notice of
the Company’s Common Stock trading at $6 per share based on a 10-day volume weighted average. The shares underlying these warrants have piggyback registration rights. 
 g) Registration Rights. The Holder shall have piggy back registration rights to register the shares underlying the Warrant. (“Piggy Back
Registration Rights”). By virtue of the Piggy Back Registration Rights, in the event that the Company plans to file a registration statement with the SEC covering shares of common stock of the Company (“Registration Statement”), the
Company shall provide written notice to Holder and Holder shall have 30 days to require in writing that all shares of common stock underlying the Warrant be covered in the Registration Statement. Notwithstanding the foregoing, the Company shall not
be obligated to include the shares underlying the Warrant in any Registration Statement if the underwriter or the party for whom the Registration Statement is being filed objects or if the Company reasonably determines that such registration may
adversely effect the registration statement or the offering. The Piggy Back Registration Rights shall be limited by applicable U.S. Securities laws, including without limitation any SEC regulation or interpretation of those laws. 
 On October 30, 2007, the Company entered into an amendment to its revolving credit facility with Laurus to
extend the Company’s access to its expanded borrowing availability under this revolving credit facility through March 31, 2008. In consideration of the extension, the Company issued to Laurus a redeemable warrant to purchase up to
4,024,398 shares with an exercise price of $2.67 per share until October 31, 2014 with piggyback registration rights. The Company has the right to terminate and cancel the warrant by making a cash payment in an amount equal to $0.99 for each
share underlying the warrant. The Company’s right to terminate and cancel the Warrant expires on the earlier of April 30, 2008 or the date of public release of unblinded clinical trial data from the current Phase 3 clinical trial of
SinuNaseTM. 
 From Amendment to Overadvance Side Letter dated 10/30/07 

(b) The Parent further agrees that if at any time after the date hereof there is not an effective Registration Statement covering all of the Third
Overadvance Warrant Shares issued hereunder and the Parent shall determine to prepare and file with the Securities and Exchange Commission a registration statement relating to an offering for its own account or the account of others under the
Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any
entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Parent shall send to Lauras written notice of such determination and, if within fifteen (15) days after receipt of such
notice, Laurus shall so request in writing, the Parent shall include in such registration statement all or any part of such Third Overadvance Warrant Shares Laurus requests to be registered, to the extent the Company may do so without violating
registration rights of others which exist as of the Amendment Effective Date (as defined below), subject to customary underwriter cutbacks applicable to all holders of registration rights and subject to obtaining any required consent of any selling
stockholder(s) to such inclusion under such registration statement. 

 On December 27, 2007 the Company issued to Hopkins Capital Group II, LLC a warrant to purchase up to 175,000 shares
of the Company’s common stock at an exercise price of $2.91 vesting immediately and having a five year term. The Company has granted the holder piggyback registration rights for the shares underlying this warrant. 
 (d) Piggyback Registration Rights. In the event that the Company plans to file a registration statement with the U. S. Securities and Exchange
Commission covering shares of common stock of the Company (“Registration Statement”), the Company shall provide written notice to Holder and Holder shall have 30 days to require in writing that all shares of common stock underlying the
Warrant, to the extent vested, be covered in the Registration Statement. Notwithstanding the foregoing, the Company shall have full discretion to determine not to include the shares underlying the warrant in any registration statement if the Company
reasonably determines that such registration may adversely effect the registration statement, the offering described in the registration statement or otherwise adversely affect the Company. 
 On June ____, 2008, the Company issued to Mayo Foundation for Medical Education and Research, a warrant to purchase up to 1,000,000 shares of the Company’s common
stock at an exercise price of 110% of the VWAP for the twenty trading days prior to exercise or $1.50 per share, vesting immediately and having a five year term. The Company has granted the holder piggyback registration rights for the shares
underlying this warrant. 
 Unfulfilled Registration Rights Agreements 
 On February 28, 2007, Accentia Biopharmaceuticals, Inc. (the “Company”) entered into definitive agreements relating to a private placement (the “Private Placement”) of $25.0 million in
principal amount of 8% Convertible Debentures due February 27, 2011 (the “Debentures”). In connection with the Private Placement, the Company and the purchasers of the Debentures entered into a Registration Rights Agreement under
which the Company is required, on or before May 29, 2007, to file a registration statement with the SEC covering the resale of the shares of Company common stock issuable pursuant to the Debentures and Warrants and to use its best efforts to
have the registration declared effective at the earliest date (but in no event later than 90 days after filing if there is no SEC review of the registration statement, or 120 days if there is an SEC review). As a result of restrictions on the
number of shares allowed to be registered pursuant to Rule 415, the Company has not yet completed the registration of all of these shares as required. However, effective on July 17, 2007 the Company filed a Registration Statement on Form S-3
which registered 10,516,652 shares pursuant to this Registration Rights Agreement, along with an amendment to the Registration Rights Agreement. 
 On
August 22, 2007 the Company entered into an agreement with McKesson Corporation. (“McKesson”) titled “Termination Agreement Re Biologics Distribution Agreement” (the “Termination Agreement”) pursuant to which
the Company and McKesson terminated the Biologics Distribution Agreement (“BDA”) entered into by the Company and McKesson as of February 27, 2004. As part of the termination of the BDA, the Company agreed to issue 1,498,128 shares of
its common stock (the “Shares”) in payment of the refundable deposit and the termination of all obligations under the BDA. The Company has agreed to register the 

 
shares within 120 days of the Closing Date (the “Registration Deadline”). This registration statement has not yet been filed and made effective,
but the need to register the shares will expire shortly after the effective date of the amendments to Rule 144, which will make these shares freely tradable on or about February 22, 2008. 
 On January 18, 2008, Accentia Biopharmaceuticals, Inc. (the “Company”) entered into definitive agreements relating to a convertible preferred stock
private placement (the “Private Placement”) of $8.7 million in principal amount. In connection with the Private Placement, the Company and the purchasers of the preferred stock entered into a Registration Rights Agreement under which the
Company is required, on or before March 18, 2008, to file a registration statement with the SEC covering the resale of the shares of Company common stock issuable pursuant to the Debentures and Warrants and to use its best efforts to have the
registration declared effective at the earliest date (but in no event later than 90 days after filing if there is no SEC review of the registration statement, or 120 days if there is an SEC review). As a result of restrictions on the number of
shares allowed to be registered pursuant to Rule 415, the Company has not yet completed the registration of all of these shares as required. However, effective on April 11, 2008, the Company filed a Registration Statement on Form S-3 which
registered 3,304,301 shares pursuant to this Registration Rights Agreement, along with an amendment to the Registration Rights Agreement. 

 SPA - Schedule 3.1(w) 
 LISTING AND MAINTENANCE REQUIREMENTS 
 The Company received notice from The NASDAQ Stock Market dated April 15,
2008, notifying the Company that it is not in compliance with NASDAQ Rule 4450(b)(1)(A), which requires a listed security to maintain a minimum $50 million market capitalization for continued trading on the NASDAQ Global Market. On May 23,
2008, Accentia’s application for transfer of the listing of its Common Stock from the NASDAQ Global Market (the “Global Market”) to the NASDAQ Capital Market (the “Capital Market”) was approved, and as of that date the
Company’s Common Stock began trading on the Capital Market and ceased trading on the Global Market. The Company’s Common Stock continues to be traded under the symbol “ABPI”. 

 Accentia Biopharmaceuticals, Inc. 
 Schedule 3.1(aa) 
 Indebtedness Summary 
 6-Jun-08 
  

							
	 	  	Principal	  	 Prior to Laurus payoff agreement
	  	 Post-Laurus payoff agreement

	Laurus secured debt pursuant to payoff agreement	  	8,800,000	  	first lien on all assets	  	first lien on Analytica International and Accentia’s BiovaxID royalty rights
				
	Midsummer One Convertible Debenture	  	8,756,944	  	no security	  	no security
				
	Midsummer Two Convertible Debenture	  	19,345,135	  	no security	  	no security
				
	Southwest LOC	  	4,000,000	  	subordinated lien on all assets	  	first lien on Accentia Pharmaceuticals inventory and receivables and 15 million Biovest shares currently owned by Accentia
				
	McKesson	  	4,133,499	  	subordinate lien on all assets	  	2 x (Guaranteed return total minus redemption payments less remaining McKesson shares times market value of Accentia stock) divided by Biovest market price = Biovest shares pledged to McKesson

				
	Guaranty of Biovest Laurus Note	  	4,900,000	  	64% of note is guaranteed by Accentia	  	Set amount of $4.9 million guaranteed

 Accentia Biopharmaceuticals, Inc. 
 Schedule 3.1(ee) 
 Accounting Firm 
 6-Jun-08 
 Cherry, Bekaert & Holland, LLP* 
 401 East Jackson Street, Suite 3400, 
 Tampa, Florida 33602 
 Telephone (813) 222-8555 - Fax (813) 222-8560 
  

	*	Effective May 2008, our former accounting firm, Aidman Piser & Company merged with Cherry, Bekaert & Holland, LLP 

 Schedule 3.1(ff) - Seniority 
 There is no indebtedness senior to the debentures with regard to collateral pledged to secure the Debentures. The following indebtedness is secured by collateral other than that pledged to secure the Debentures: 
 Laurus Master Fund, Ltd. retains a first security interest all of the capital stock and assets of Analytica International, Inc. and all of the royalty interest and
rights in the BiovaxID Royalty Agreement 
 Southwest Bank f/k/a Missouri State Bank retains a first security interest in 15 million common stock shares
of Biovest International, Inc. owned by the Company and all of the accounts receivable and inventory of TEAMM Pharmaceuticals, Inc. d/b/a Accentia Pharmaceuticals. 
 McKesson Corporation retains a first security interest in 18 million common stock shares of Biovest International, Inc. owned by the Company 
 The September 2006 Debenture Holders retain a first security interest in 18 million common stock shares of Biovest International, Inc. owned by the Company 

 Schedule 3.1(kk) – Noncompliant FDA Products 
 Respi~TANN products are marketed by the Company in the United States without an FDA-approved marketing application because they have been considered by us to be identical, related, or similar to products that have
existed in the market without an NDA or ANDA. This product is marketed subject to the FDA’s regulatory discretion and/or enforcement policies. FDA has adopted a risk-based enforcement policy concerning unapproved drugs. The agency has
articulated that, in enforcing the new drug application requirements, it prioritizes drugs that pose potential safety risks, lack evidence of effectiveness and prevent patients from seeking effective therapies, and those that are marketed
fraudulently. In addition, the FDA has indicated that approval of an NDA for one drug within a class of drugs marketed without FDA approval may also trigger agency enforcement of the new drug requirements. Once the FDA issues an approved NDA for one
of the drug products at issue or completes the efficacy review for that drug product, it may require us to also file a NDA or ANDA application for that same drug in order to continue marketing it in the United States. While the agency generally
provides sponsors a one year grace period, the agency is not statutorily required to do so. In addition, although we may be given time to submit a marketing application before the agency would take enforcement action, the time it takes us to
complete the necessary clinical studies and submit an application to FDA may exceed this time period, resulting in an interruption of marketing. It is also possible that the FDA could disagree with our determination that this product is identical,
related, or similar to products that have existed in the marketplace without an NDA or ANDA. 
 In addition, some or all of the Respi~TANN product marketed
by the Company contain a timed-release dosage mechanism utilizing tannic acid. In 1960, the FDA issued a policy stating that when a timed-release dosage feature is added to a drug, then an approved NDA is required in order to market the drug. While
listed in the Code of Federal Regulations, this policy has never gone through the notice and comment rulemaking process required for the development of an FDA regulation. Additionally, numerous tannic-acid based medications have been introduced by
other pharmaceutical companies since the FDA’s pronouncement without an NDA. Consequently, in continuing to market this product, we rely on the FDA’s enforcement discretion with respect to the product, but we cannot guarantee that the FDA
will not in the future choose to require an NDA or ANDA for the product, notwithstanding the fact that similar products have been marketed for many years. 
 In the May 29, 2007, Federal Register the FDA issued a statement on extended release products containing guaifenesin and its intention to take enforcement action against drug products in time-released forms containing guaifenesin that
are not subject to a formal approved New Drug Application (NDA). Only one firm, Adams Respiratory Therapeutics, has obtained approved NDAs for products in timed-release dosage forms containing guaifenesin. These products are sold under the trade
names of MUCINEX and HUMIBID. The FDA stated that unapproved time-released products containing guaifenesin could no longer be manufactured after August 2, 2007 nor distributed on or after November 26, 2007. 
 At the time the Federal Register was made public, it was our opinion and the opinion of the manufacturer of Respi-TANN G, Kiel Laboratories, that this ruling did not
affect Respi-TANN G. This opinion was based on the fact that the guaifenesin in Respi-TANN G is in an immediate released form, not an extended released form. Based on further internal review of the Federal Register document and further clarification
from the FDA Accentia management made a corporate decision to stop distribution, promotion and manufacture of Respi-TANN G effective November 26, 2007. On November 26, 2007, the Company instructed its distributor of record, DDN
Pharmaceutical Logistics, to place the existing inventory of Respi-TANN G, both trade and sample inventories, on hold. Furthermore, the Company instructed the Accentia sales force to cease promotion and sampling of Respi-TANN G effective
immediately. In addition, the Company’s management communicated with all wholesalers about this decision with regard to DDN Pharmaceutical Logistics no longer shipping Respi-TANN G. 

 Accentia Biopharmaceuticals, Inc. 
 Schedule 4.9 
 Use of Proceeds Other Than Working Capital Purposes 
 6-Jun-08 
 All proceeds will be used for the following: 
  

	*	working capital 

  

	*	monthly McKesson share redemption of approximately $106,800 

  

	*	litigation expense not to exceed $75,000 

  

	*	monthly Southwest bank loan interest of approximately $28,000Preferability letter regarding change in accounting principle

 Exhibit 10.54 
 June 20, 2008 
 Board of Directors 
 Wise Metals
Group LLC 
 857 Elkridge Landing Road, Suite 600 
 Linthicum, MD
21093 
 Dear Directors: 
 We are providing this letter to you
for inclusion as an exhibit to your Form 10-Q filing pursuant to Item 601 of Regulation S-K. 
 We have been provided a copy of the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2008. Note 5 therein describes a change in accounting principle for the amortization of the unrecognized gain/loss from the standard amortization methodology under FAS 106 and FAS 87,
which is a methodology of amortizing the net gain or loss that exceeds 10 percent of the greater of the accumulated postretirement benefit obligation or the market-related value of plan assets over the remaining service period, to a methodology of
fully recognizing any gain or loss in excess of 45% of the greater of (1) Accumulated Post-Retirement Benefit Obligation (“APBO”) and (2) market value of assets (“MVA”) and amortizing any gain or loss between
10%—45% of the greater of (1) APBO and (2) MVA over the remaining service period. It should be understood that the preferability of one acceptable method of accounting over another for the amortization of unrecognized gains/losses has
not been addressed in any authoritative accounting literature, and in expressing our concurrence below we have relied on management’s determination that this change in accounting principle is preferable. Based on our reading of
management’s stated reasons and justification for this change in accounting principle in the Form 10-Q, and our discussions with management as to their judgment about the relevant business planning factors relating to the change, we concur with
management that such change represents, in the Company’s circumstances, the adoption of a preferable accounting principle in conformity with Statement of Financial Accounting Standards No. 154, Accounting Changes and Error
Corrections. 
 We have not audited any financial statements of the Company as of any date or for any period subsequent to December 31, 2007.
Accordingly, our comments are subject to change upon completion of an audit of the financial statements covering the period of the accounting change. 
  

	
	Very truly yours,
	
	/s/ PricewaterhouseCoopers LLP
	PricewaterhouseCoopers LLP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]